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ABSTRACT: Adult vampire bats (Desmodus rotundus) were vaccinated by intramuscular, scarifi-
cation, oral, or aerosol routes (n58 in each group) using a vaccinia-rabies glycoprotein recom-
binant virus. Sera were obtained before and 30 days after vaccination. All animals were then
challenged intramuscularly with a lethal dose of rabies virus. Neutralizing antirabies antibodies
were measured by rapid fluorescent focus inhibition test (RFFIT). Seroconversion was observed
with each of the routes employed, but some aerosol and orally vaccinated animals failed to
seroconvert. The highest antibody titers were observed in animals vaccinated by intramuscular
and scarification routes. All animals vaccinated by intramuscular, scarification, and oral routes
survived the viral challenge, but one of eight vampire bats receiving aerosol vaccination suc-
cumbed to the challenge. Of 31 surviving vaccinated and challenged animals, nine lacked de-
tectable antirabies antibodies by RFFIT (five orally and four aerosol immunized animals). In
contrast, nine of 10 non-vaccinated control bats succumbed to viral challenge. The surviving
control bat had antiviral antibodies 90 days after viral challenge. These results suggest that the
recombinant vaccine is an adequate and safe immunogen for bats by all routes tested.
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INTRODUCTION
Rabies is a fatal viral encephalitis that
affects wild and domestic homeothermic
species, including humans (Soulebot et al.,
1982). While rabies in domestic animals
has been controlled in industrialized coun-
tries by parenteral vaccination (Acha and
Arambulo, 1985), rabies in wildlife has
been more difficult to control and has re-
mained an important public health prob-
lem (Brochier et al., 1989). Even countries
that have successfully controlled domestic
animal rabies still face the threat of rabies
virus reservoirs in wild animals such as red
foxes (Vulpes vulpes) in Europe, or rac-
coons (Procyon lotor) and bats in North
America (Toma and Andral, 1977; Rup-
precht et al., 1988; Pastoret et al., 1995).
Strategies for control of sylvatic rabies
have been concentrated on development
of practical methods of oral vaccination of
wild rabies reservoir species. Oral bait vac-
cination of foxes led to virtual elimination
of sylvatic rabies in Europe (Brochier et
al., 1991).
Bats are frequent lyssavirus hosts, and
insectivorous bats play an important role
in the epidemiology of rabies and rabies-
like lyssaviruses (Burns and Farinacci,
1955; Baer and Smith, 1991). Twenty-one
of 36 cases of human rabies reported in
the United States since 1980 were associ-
ated with nonhematophagous bats. Al-
though Eptesicus spp. and Myotis spp. are
the most common insectivorous bat spe-
cies associated with rabies, 15 (71%) of 21
human cases were associated with silver-
haired bats (Lasionycteris noctivagans;
Morimoto et al., 1996; Noah et al., 1998;
Haupt, 1999). In contrast, in Latin Amer-
ica, a single species of hematophagous
bats, the common vampire (Desmodus ro-
tundus), is the primary wild host and vec-
tor affecting human beings and domestic
animals. Since 1975, 500 cases of human
rabies associated with vampire bat species
were reported in Latin America. These
540 JOURNAL OF WILDLIFE DISEASES, VOL. 38, NO. 3, JULY 2002
bats are associated with about 100,000 cas-
es of bovine rabies each year (Acha and
Arambulo, 1985; Flores Crespo, 1991;
Pan-American Health Organization, 1991;
Navarrete Navarro et al., 1999). System-
atic elimination of vampire bats is unfea-
sible, as was demonstrated in a project us-
ing anticoagulants (Acha and Malaga Alba,
1988; Lord, 1988) and would also affect
beneficial bats. An alternative strategy,
such as vaccination (Lord, 1988), that
would respect the ecologic role of bats, ap-
pears more attractive (Aguilar-Setién et al.,
1998).
Insertion of a glycoprotein rabies virus
gene in vaccinia virus enhances vaccine ef-
ficacy (Brochier et al., 1989, 1991; Pastoret
et al., 1995). Rabies virus glycoprotein
gene insertion removes the thymidin ki-
nase gene from the vaccinia virus vector
rendering it less pathogenic than its pre-
decessor (Kieny et al., 1984; Boulanger et
al., 1995). Recombinant vaccinia–rabies
glycoprotein (V-RG) vaccine is immuno-
genic, stable, and safe, although an inci-
dental, non-fatal case of human infection
due to exposure to recombinant vaccinia-
rabies glycoprotein virus was recently re-
ported (Rupprecht et al., 2001). Vaccina-
tion with V-RG, if effective, could help
control rabies and reduce human and an-
imal mortality. We tested immunogenicity
and safety of V-RG vaccine when delivered




Diagnosis of rabies was established in brain
smears by fluorescent antibody testing (FAT) as
recommended by the World Health Organiza-
tion (Dean and Abelseth, 1973).
Animals
Common vampire bats (weight 30–45 g)
were captured from shelters located in Tehu-
acán (188339000N, 978529380W) and Taxco
(188349050N, 998379230W), Mexico. Bats were
confined in biosafety level II security housing
at constant temperature (2362.5 C) and 70%
relative humidity. All bats went through a 30-
day captivity-habituation period prior to the
study. Of 90 seronegative bats, 20 died within
the first 11 days of captivity. None of these an-
imals had rabies. The rest adapted well. Eleven
pregnant bats were excluded from the study.
Four gave birth and their offspring were used
to test vaccine safety. Bats were fed defibrin-
ated blood from healthy cattle and pigs. Fif-
teen-20 ml of blood (with multivitamin, Clusi-
volt, Wyeth, S. A. de C. V., Mexico), 1.5 ml/l
added) in 200 ml bottles were provided daily
to each bat.
Vaccine
V-RG vaccine (VVTGgRAB-26D3), the re-
sult of combining vaccinia modified-virus (Co-
penhagen strain) with rabies virus (ERA strain)
glycoprotein, was employed (Pincali and Pa-
oletti, 1982; Kieny et al., 1984). Vaccine (lot
5L24, manufactured on June 15, 1987, contain-
ing 108 cell culture infecting doses/ml), was re-
constituted as previously described (Aguilar-Se-
tién et al., 1998).
Vaccination protocol
Four groups comprising eight adult vampires
each were vaccinated as follows: group A, in-
tramuscular (IM); group B, scarification; group
C, oral; and group D, aerosol. Group E con-
sisted of 10 control animals (PBS injected). For
groups A and B, lyophilized V-RG vaccine was
suspended in 1 ml of distilled water. Group A
animals were injected IM once in the dorsal
muscle at the level of the scapular cartilage
with 0.25 ml of V-RG vaccine. In group B, one
drop (0.1 ml) of vaccine was applied once to a
1.531.5 cm scarified area in the ventral skin of
the right wing. In group C, lyophilized V-RG
vaccine (108 CCID50) was resuspended in one
ml of defibrinated bovine blood lacking rabies
antibodies (Smith et al., 1973), and after 48 hr
fasting, 1 ml blood was delivered once directly
into the bat’s mouth with a needle-free syringe.
In group D, lyophilized V-RG vaccine (108
CCID50) was first resuspended in 1 ml of dis-
tilled water and then diluted in 20 ml of phos-
phate buffered saline (PBS, pH 7.4). This ma-
terial was placed in a nebulizer (DeVilbiss R,
Ohio, USA, particle size 3–5 mm) connected to
a hermetic plastic chamber (30340315 cm)
with a hose, the latter connected to a chlorine
trap. Bats were placed in the chamber and ex-
posed to a 15 min nebulization, during which
5 ml of diluted V-RG vaccine was consumed by
the nebulizer. The adult control bats received
0.25 ml PBS IM 30 days prior to viral chal-
lenge.
Two of four nursing 1 wk old vampire bats
were inoculated IM with one V-RG vaccine
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TABLE 1. Seroconversion (antibodies detected in adult vampire bats by rapid fluorescent focus inhibition













































































FIGURE 1. Kaplan-Meier survival rates of vacci-
nated and non-vaccinated (control) vampire bats.
dose (104 CCID50). These bats were not chal-
lenged with rabies virus.
Serology
Blood was drawn from the marginal vein of
the forearm membrane and serum obtained by
centrifugation. All animals were bled the day
before and 30 days after vaccination (Aguilar-
Setién et al., 1998). A surviving bat from each
group was also bled at the end of the experi-
ment. Neutralizing antibody titers against ra-
bies virus were measured by the rapid fluores-
cent focus inhibition test (RFFIT, sensitivity
0.25 IU/ml; Smith et al., 1973) and were ex-
pressed as international units per ml (IU/ml)
when compared with a standard reference se-
rum. An antibody concentration of 0.5 IU ml
is considered protective in humans (Smith et
al., 1973).
Virus challenge
Animals were challenged 31 days after vac-
cination or PBS administration. The rabies vi-
rus variant CASS88, isolated in 1988 from a
rabid vampire bat (Instituto Nacional de Inves-
tigaciones Forestales y Agropecuarias, Mexico
City, Mexico), was employed (Cuevas Romero
et al., 1989). The genome of this variant virus
was characterized as a vampire bat strain, and
its lethality by the IM route for adult vampire
bats established in the same work (Aguilar-Se-
tién et al., 1998). Virus challenge consisted of
a single 106 mouse intracerebral 50% lethal
dose (MICLD50, 21-day old BALB/C mice) 4
mm deep IM injection in the muscle at the site
of the scapular cartilage (Aguilar-Setién et al.,
1998). Animals were observed daily to assess
their health (depression, incoordination, trem-
or, and blood consumption) for 90 days after
viral challenge, and those surviving this period
were euthanized with ether and autopsied
(Commission of Life Sciences, 1996).
Statistical analysis of results
Survival rates between the control group E,
and the vaccinated groups were analyzed by
Kaplan-Meier test and differences in antibody
levels between groups were statistically com-
pared using the non-parametric Mann–Whit-
ney test (Dawson-Saunders and Trapp, 1994).
RESULTS
Seroconversion rates 31 days after vac-
cination are shown in Table 1. Serocon-
version rates were significant (P,0.0002)
only in groups A (IM) and B (scarifica-
tion), when compared to control group E.
Orally and aerosol-vaccinated animals se-
roconverted less vigorously than animals
vaccinated IM or by scarification (Table 1).
Protection against viral challenge is
shown in Figure 1. All vaccinated animals
survived the rabies virus challenge
(P,0.0001), except for a single aerosol-
vaccinated bat that lacked detectable an-
542 JOURNAL OF WILDLIFE DISEASES, VOL. 38, NO. 3, JULY 2002
tibodies. Nine of 31 surviving vaccinated
bats lacked detectable antirabies antibod-
ies by RFFIT (five orally and four aerosol
immunized) when tested 30 days post-vac-
cination. Nine (90%) of 10 control bats
succumbed to viral challenge. Sera ob-
tained from one bat in each group, 90 days
after viral challenge had $10 IU of anti-
rabies antibodies.
No clinical signs attributable to vacci-
nation were observed except few small
crusts at the scarification site found in
group B. None of the rabid vampire bats
exhibited aggressive behavior (i.e., threat-
ening attitudes, biting between infected
animals, etc.). Clinical signs of anxiety, al-
tered reflexes, tremor, and paralysis were
observed 72–24 hr before death occurred.
All animals alive 90 days after challenge
appeared healthy and were feeding nor-
mally (15–20 ml/day). No evidence of ra-
bies was found by FAT at autopsy 90 days
after challenge.
DISCUSSION
With the exception of the single aerosol
vaccinated bat, all vaccinated animals sur-
vived the rabies virus challenge. Not all
surviving animals had detectable anti-ra-
bies antibodies by RFFIT 30 days post-
vaccination. As expected, the IM and the
scarification routes were more effective in
leading to seroconversion than the more
practical oral and aerosol routes. Thus, the
recombinant V-RG vaccine appears to pro-
tect most vampire bats against experimen-
tal rabies irrespective of the immunization
route employed.
Conventional rabies vaccines may be
pathogenic for small mammals (Artois et
al., 1992). Our results confirm efficacy and
safety of V-RG vaccine when applied to
adult and nursing hematophagous bats
(Brochier et al., 1989).
An antibody titer of 0.5 IU ml is indic-
ative of successful rabies immunization in
humans (Smith et al., 1973). Protective
levels may be lower in vampire bats when
using V-RG vaccine, however, because
protection was found even in bats with un-
detectable antibody levels. Cellular im-
munity and/or natural immune mecha-
nisms may be important in rabies virus in-
fection (Medzhitov and Janeway, 2000)
and must therefore be studied in these an-
imals. Absence of antibodies prior to viral
challenge appears to be dependable evi-
dence of lack of exposure to rabies virus,
but does not constitute absolute proof that
an animal had no prior exposure to rabies
virus (Prabhakar and Nathanson, 1981).
We speculate that the single surviving bat
in the control group developed protective
antirabies antibody as a result of an un-
expected booster effect. On the other
hand, protection in the absence of anti-
body has been reported in foxes vaccinat-
ed orally with V-RG vaccine (Pastoret et
al., 1992).
Because some bats without antibodies
were protected against rabies virus chal-
lenge, evaluation of vaccine efficacy in the
field will have to rely on epidemiologic and
demographic rather than serologic evi-
dence.
Our data support previous reports that
bats are more resistant to rabies (and other
lyssaviruses) than species such as dogs and
foxes; 103 MICLD50 of the ‘‘vulpine’’ ho-
mologous rabies virus variant is capable of
killing 80% of red foxes (Blancou et al.,
1979) whereas 106 MICLD50 of CASS88
‘‘vampire bat’’ homologous variant is re-
quired in order to kill 80% of vampire bats
(Moreno and Baer, 1980; Aguilar-Setién et
al., 1998; McColl et al., 2000).
A preliminary study reported V-RG vac-
cine in bats produced a short-term sero-
conversion around 18–30 days post-vacci-
nation (Aguilar-Setién, 1998). This mea-
sured antibodies 30 days after vaccination.
In the future, antibody levels and protec-
tion beyond 30 days after vaccination
should be studied, in order to establish du-
ration of immunity, as well as to evaluate
the need for boosters.
Vaccination of hematophagous bats
could increase the epizootic threshold for
rabies propagation (Anderson, 1982), and
result in the need for removal of fewer an-
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imals in traditional rabies control cam-
paigns based on reduction of species pop-
ulations. Lord (1988) recommended vam-
pire vaccination as a suitable method for
the control of rabies because: ‘‘. . . an im-
munized animal is doubly valuable because
it not only cannot maintain the epizootic,
but also because it continues to occupy its
habitat niche, defending it against invad-
ers . . .’’. Even if vampire rabies is con-
trolled, the possibility remains that the vi-
rus will find other susceptible bat species.
Therefore, attractive as vampire bat vac-
cination appears to be, questions such as
bat population dynamics, intra/interspecies
rabies dissemination within Chiroptera,
and rabies strain variation that may limit
vaccination efficacy, remain unanswered.
Aerosol vaccination in shelters shared by
various bat species may be a convenient
strategy for reducing transmission of rabies
to the other species. A combined strategy
of vaccination and limited population re-
ductions, such as was applied to foxes by
Bogel et al. (1981), may lead to control of
bat-transmitted rabies.
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